View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 29, 2021

NeuroRx’s Zyesami meets primary endpoint in Covid-19 trial

NeuroRx has reported that the Phase IIb/III trial of intravenously administered Zyesami (aviptadil acetate) for treating respiratory failure in critically ill Covid-19 patients met the primary endpoint.

NeuroRx has reported that the Phase IIb/III trial of intravenously administered Zyesami (aviptadil acetate) for treating respiratory failure in critically ill Covid-19 patients met the primary endpoint.

A synthetic form of human vasoactive intestinal polypeptide (VIP), Zyesami is being developed in partnership with Relief Therapeutics.

The randomised, double-blind, multi-centre, placebo-controlled trial enrolled 196 participants at ten US hospitals.

According to the latest 60-day results, Zyesami met the primary endpoint of successful recovery from respiratory failure at day 28 in all subjects and showed a meaningful survival benefit after controlling for ventilation status and treatment site.

Clinically and statistically significant recovery from respiratory failure was observed in prespecified analysis in the 127 subjects treated with high flow nasal cannula (HFNC) versus those treated with mechanical or non-invasive ventilation at tertiary care hospitals.

In this group, subjects receiving Zyesami had a 71% chance of successful recovery by day 28 versus 48% in the placebo group. By day 60, the Zyesami group had a 75% rate of successful recovery versus 55% in the placebo group.

Furthermore, 84% of HFNC patients at tertiary medical centres receiving Zyesami survived to day 60 versus 60% receiving placebo.

Based on the latest data, NeuroRx intends to submit an application for Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA) and a New Drug Application (NDA), consequently.

NeuroRx chairman and CEO professor Jonathan Javitt said: “Zyesami has now demonstrated itself in a Phase II/III trial, conducted under FDA Fast Track Designation, not only to shorten hospitalisation (as was previously reported) but also to save lives and increase the likelihood of patients returning safely home to their families.

“In exactly 12 months, a lifesaving drug has advanced from concept to clinical success in partnership with Relief Therapeutics in the midst of a public health emergency that has claimed the lives of millions.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena